30
California governor vetoes bill that would have set a $35 cap for insulin
(www.theguardian.com)
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
this post was submitted on 09 Oct 2023
30 points (100.0% liked)
News
19 readers
12 users here now
Breaking news and current events worldwide.
founded 1 year ago
There are different types of insulin that work differently. Not only are there short, medium, and long acting insulins, but quite a few people have to take multiple insulins. The CalRX insulin will be great, but it's not going to be the answer for everyone. The insulin cap law would've helped.
Just an FYI. The CalRx insulin is being produced by Civica Rx. They will be producing three insulins for the program. Glargie, Lispro, and Aspart. These are generic biologics that are interchangeable with Lantus (long-acting), Humalog (fact-acting), and Novolog (instant). Additionally, for the products where this makes sense, products will be available in vial and autoinjector formats. The $30 price is that of the vials and $55 for a box of five autoinjectors.
So main take aways should be CalRx will be producing analogs and will be providing a wide band of types for different needs.
Humalog (lispro) is approximately the same as Novolog (aspart). There are rapid actings, they are Fiasp and Lyumjev.
People with type 1 pretty much always take a long acting like Lantus and a fast like Novolog, unless you have a pump, in which case it's only fast acting. But I'm sure they've thought of that.